Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Lymphoma

Free Subscription Articles published in Blood Retrieve available abstracts of 221 articles: HTML format

Single Articles

September 2025
1. ZUCCA E, Ceriani L, Ciccone G, Di Rocco A, et al
   Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.
   Blood. 2025 Sep 12:blood.2025028823. doi: 10.1182/blood.2025028823.
   PubMed     Abstract available
   
   
   
2. 
   Chavez JC, Dickinson M, Munoz J, et al. Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood. 2025;145(20):2303-2311.
   Blood. 2025;146:1374.
   PubMed    
   
   
   
3. FALCHI L, Sureda A, Leppa S, Vermaat JS, et al
   Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma.
   Blood. 2025 Sep 8:blood.2025029909. doi: 10.1182/blood.2025029909.
   PubMed     Abstract available
   
   
   
4. HAVRANEK O
   Classic Hodgkin lymphoma: the journey over the destination.
   Blood. 2025;146:1152-1153.
   PubMed    
   
   
   
5. TATTERTON DJ, Newby ML, Allen JD, Sale BJ, et al
   The Origin, Diagnosis, and Prognosis of Oligomannose-Type Diffuse Large B-Cell Lymphoma.
   Blood. 2025 Sep 2:blood.2025029163. doi: 10.1182/blood.2025029163.
   PubMed     Abstract available
   
   
   
6. PAL I, Illendula A, Joyner AM, Manavalan JS, et al
   Nanoromidepsin, a Polymer Nanoparticle of the HDAC Inhibitor, Improves Safety and Efficacy in Models of T-cell Lymphoma.
   Blood. 2025 Sep 2:blood.2024027997. doi: 10.1182/blood.2024027997.
   PubMed     Abstract available
   
   
   August 2025
7. SCHERER F
   Cracking the POD24 code in follicular lymphoma.
   Blood. 2025;146:899-900.
   PubMed    
   
   
   
8. 
   Allo-HCT in Hodgkin lymphoma after CPI.
   Blood. 2025;146:1030.
   PubMed    
   
   
   
9. XU P, Zhu Y, Shi ZY, Wang L, et al
   A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma.
   Blood. 2025 Aug 19:blood.2025028649. doi: 10.1182/blood.2025028649.
   PubMed     Abstract available
   
   
   
10. CASULO C, Sehn LH
    Treatment of Relapsed and Refractory Follicular Lymphoma: Which Treatment for Which Patient for Which Line of Therapy?
    Blood. 2025 Aug 14:blood.2024026018. doi: 10.1182/blood.2024026018.
    PubMed     Abstract available
    
    
    
11. QIU L, Thakral B
    Intrasinusoidal pleomorphic mantle cell lymphoma mimicking intravascular large B-cell lymphoma.
    Blood. 2025;146:897.
    PubMed    
    
    
    
12. REJESKI K, Sanz J, Fei T, Nair MS, et al
    T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy.
    Blood. 2025;146:834-846.
    PubMed     Abstract available
    
    
    
13. SAM J, Leclercq-Cohen G, Gebhardt S, Surowka M, et al
    Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.
    Blood. 2025 Aug 1:blood.2025028863. doi: 10.1182/blood.2025028863.
    PubMed     Abstract available
    
    
    July 2025
14. JAAFAR C, Ethiraj P, Qiu Z, Lin AP, et al
    alpha-Ketoglutarate promotes amino acid depletion and suppresses B-cell lymphoma growth and development.
    Blood. 2025 Jul 23:blood.2024028069. doi: 10.1182/blood.2024028069.
    PubMed     Abstract available
    
    
    
15. WANG W, Cai Q, Liu Y, Nie L, et al
    TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma.
    Blood. 2025 Jul 23:blood.2024026919. doi: 10.1182/blood.2024026919.
    PubMed     Abstract available
    
    
    
16. KITTAI AS, Marchetti M, Al-Sawaf O, Benjamini O, et al
    International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.
    Blood. 2025;146:291-303.
    PubMed     Abstract available
    
    
    
17. ALDERUCCIO JP, Noy A
    The Treatment of Marginal Zone Lymphoma.
    Blood. 2025 Jul 15:blood.2024028269. doi: 10.1182/blood.2024028269.
    PubMed     Abstract available
    
    
    
18. BROOKS TR, Zabor EC, Bedelu Y, Yang X MD, et al
    Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.
    Blood. 2025 Jul 15:blood.2025029117. doi: 10.1182/blood.2025029117.
    PubMed     Abstract available
    
    
    
19. SCARISBRICK JJ, Quaglino P, Whittaker SJ, Bagot M, et al
    A New Prognostic Index (CLIPI) for Advanced Cutaneous Lymphoma Enables Precise Patient Risk Stratification.
    Blood. 2025 Jul 15:blood.2025029628. doi: 10.1182/blood.2025029628.
    PubMed     Abstract available
    
    
    
20. KAULEN LD, Martinez-Lage M, Abramson JS, Karschnia P, et al
    Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy.
    Blood. 2025 Jul 15:blood.2025028964. doi: 10.1182/blood.2025028964.
    PubMed     Abstract available
    
    
    
21. AL JABRI M, Sakhdari A
    A rare phenotype of peripheral T-cell lymphoma, NOS: coexpression of CD15, CD20, and T follicular helper markers in a DUSP22alt case.
    Blood. 2025;146:260.
    PubMed    
    
    
    
22. YANG H, Zhang W, Ravanmehr V, Cui G, et al
    Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement.
    Blood. 2025;146:191-205.
    PubMed     Abstract available
    
    
    
23. PERALES MA, Awan FT, Boumendil A, Patel J, et al
    Outcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis.
    Blood. 2025 Jul 7:blood.2024027197. doi: 10.1182/blood.2024027197.
    PubMed     Abstract available
    
    
    June 2025
24. RAI S, Duns G, Frontzek F, Wong JCH, et al
    Somatic IRF4 Mutations and Thymic Tropism in Primary Mediastinal Large B-cell Lymphoma.
    Blood. 2025 Jun 20:blood.2025028412. doi: 10.1182/blood.2025028412.
    PubMed     Abstract available
    
    
    
25. FREEMAN CL, Srinivasan S, Hodkinson B, Deshpande S, et al
    Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status.
    Blood. 2025;145:3052-3056.
    PubMed     Abstract available
    
    
    
26. MULLER F, Schwingen NR, Hagen M, Scholz JK, et al
    Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma.
    Blood. 2025 Jun 12:blood.2025028375. doi: 10.1182/blood.2025028375.
    PubMed     Abstract available
    
    
    
27. SELVARAJAH S, Xia D
    A small B-cell leukemia/lymphoma with weak to negative expression of CD5.
    Blood. 2025;145:2931.
    PubMed    
    
    
    
28. CLAUDEL A, Cottereau AS, Bachy E, Itti E, et al
    Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.
    Blood. 2025 Jun 11:blood.2024027727. doi: 10.1182/blood.2024027727.
    PubMed     Abstract available
    
    
    
29. HAWKES EA, Gregory GP
    Burkitt lymphoma: click here to add to CAR-T?
    Blood. 2025;145:2678-2680.
    PubMed    
    
    
    
30. TOOZE R, Klein U
    Exploiting tumor-derived IL-10 activity in lymphoma therapy.
    Blood. 2025;145:2676-2678.
    PubMed    
    
    
    
31. KITAGAWA Y, Jaffe ES
    Classic Hodgkin lymphoma in the cerebellum: a rare site for a common disease.
    Blood. 2025;145:2799.
    PubMed    
    
    
    May 2025
32. SHAH B, Nejati R
    Unveiling the enigma: circulating flowerlike large B-lymphoma cells in the context of angioimmunoblastic T-cell lymphoma.
    Blood. 2025;145:2671.
    PubMed    
    
    
    
33. REED HD, Do H, Weller E, Harris MH, et al
    Lymphoid malignancies in patients with Shwachman-Diamond syndrome.
    Blood. 2025;145:2528-2532.
    PubMed     Abstract available
    
    
    
34. TUMULURU S, Godfrey JK, Cooper A, Yu J, et al
    Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response.
    Blood. 2025;145:2460-2472.
    PubMed     Abstract available
    
    
    
35. YOSHIMITSU M, Choi I, Kusumoto S, Shimokawa M, et al
    A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma.
    Blood. 2025 May 15:blood.2024027902. doi: 10.1182/blood.2024027902.
    PubMed     Abstract available
    
    
    
36. PARRY EM, Okosun J
    An Updated Understanding of Follicular Lymphoma Transformation.
    Blood. 2025 May 15:blood.2024026016. doi: 10.1182/blood.2024026016.
    PubMed     Abstract available
    
    
    
37. WANG X, Yi H
    Adult T-cell leukemia/lymphoma coexistent with immune dysregulation-associated EBV+ lymphoproliferative disorder.
    Blood. 2025;145:2396.
    PubMed    
    
    
    
38. PELZL R, Benintende G, Gsottberger F, Scholz JK, et al
    Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.
    Blood. 2025 May 13:blood.2024027877. doi: 10.1182/blood.2024027877.
    PubMed     Abstract available
    
    
    
39. PIROSA MC, Bruscaggin A, Terzi di Bergamo L, Salehi M, et al
    A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNA.
    Blood. 2025 May 13:blood.2024027355. doi: 10.1182/blood.2024027355.
    PubMed     Abstract available
    
    
    
40. 
    Lee HJ, Ramchandren R, Friedman J, et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood. 2025;145(3):290-299.
    Blood. 2025;145:2231.
    PubMed    
    
    
    
41. DU MQ
    EMZL at various sites: learning from each other.
    Blood. 2025;145:2117-2127.
    PubMed     Abstract available
    
    
    
42. PARISI X, Medeiros LJ
    When lymphoma mimics adenocarcinoma: signet ring morphology in follicular lymphoma.
    Blood. 2025;145:2104.
    PubMed    
    
    
    
43. CHAPUY B, Wood T, Stewart C, Dunford A, et al
    DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma.
    Blood. 2025;145:2041-2055.
    PubMed     Abstract available
    
    
    April 2025
44. MARCO-AYALA J, Ortuno FJ
    Appearances deceive: unmasking mantle cell lymphoma with prolymphocytic morphology.
    Blood. 2025;145:1701.
    PubMed    
    
    
    
45. BRODY JD, Jorgensen J, Belada D, Costello R, et al
    Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.
    Blood. 2025;145:1621-1631.
    PubMed     Abstract available
    
    
    
46. STEIDL C
    The immunotherapy real estate of Hodgkin lymphoma.
    Blood. 2025;145:1445-1447.
    PubMed    
    
    
    
47. GOTTSCHLICH A, Grunmeier R, Hoffmann GV, Nandi S, et al
    Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma.
    Blood. 2025;145:1536-1552.
    PubMed     Abstract available
    
    
    
48. TOPP MS, Matasar M, Allan JN, Ansell SM, et al
    Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.
    Blood. 2025;145:1498-1509.
    PubMed     Abstract available
    
    
    March 2025
49. BAKHSHI TJ, Pina-Oviedo S
    Warthin-Finkeldey cells seen in a setting other than measles: chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Blood. 2025;145:1437.
    PubMed    
    
    
    
50. ARAUJO-AYALA F, Beguelin W
    Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics.
    Blood. 2025 Mar 16:blood.2024026020. doi: 10.1182/blood.2024026020.
    PubMed     Abstract available
    
    
    
51. KIM SJ, Lim JQ, Yoon SE, Yang DH, et al
    Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma.
    Blood. 2025 Mar 12:blood.2024027109. doi: 10.1182/blood.2024027109.
    PubMed     Abstract available
    
    
    
52. PRATS-MARTIN C, Morales-Camacho RM
    Prolymphocytic progression of splenic marginal zone lymphoma.
    Blood. 2025;145:1097.
    PubMed    
    
    
    
53. GONZALEZ MANCERA M, Silva O
    ALK+ anaplastic large cell lymphoma expressing CD33 and myeloid nuclear differentiation antigen.
    Blood. 2025;145:1098.
    PubMed    
    
    
    
54. LI W, Wang R, Wang J, Chai D, et al
    Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation.
    Blood. 2025;145:1047-1060.
    PubMed     Abstract available
    
    
    February 2025
55. DI M, Maurer MJ, Flowers CR
    End points and Outcomes in Follicular Lymphoma: What should we measure, how, and why?
    Blood. 2025 Feb 28:blood.2024026978. doi: 10.1182/blood.2024026978.
    PubMed     Abstract available
    
    
    
56. MULVEY E, Rutherford SC, Leonard JP
    The Future of Follicular Lymphoma Management: Strategies on the Horizon.
    Blood. 2025 Feb 28:blood.2024026017. doi: 10.1182/blood.2024026017.
    PubMed     Abstract available
    
    
    
57. NGUYEN VTM, Namba H, Porter H, Shlyueva D, et al
    Synergistic antitumor effect of combined EZH2 and DOT1L inhibition in B-cell lymphoma.
    Blood. 2025 Feb 26:blood.2024026534. doi: 10.1182/blood.2024026534.
    PubMed     Abstract available
    
    
    
58. AL JABRI M, Chang H
    Blastoid variant of double-hit lymphoma masquerading as acute lymphoblastic leukemia.
    Blood. 2025;145:897.
    PubMed    
    
    
    
59. ARMAND P
    Introduction to a review series on mantle cell lymphoma: sands shifting in the darkness.
    Blood. 2025;145:653-654.
    PubMed    
    
    
    
60. JAIN P, Wang M
    High-risk MCL: recognition and treatment.
    Blood. 2025;145:683-695.
    PubMed     Abstract available
    
    
    
61. SILKENSTEDT E, Dreyling M
    Treatment of relapsed/refractory MCL.
    Blood. 2025;145:673-682.
    PubMed     Abstract available
    
    
    
62. SARKOZY C, Tessoulin B, Chiron D
    Unraveling MCL biology to understand resistance and identify vulnerabilities.
    Blood. 2025;145:696-707.
    PubMed     Abstract available
    
    
    
63. LEWIS CS, Barraclough A, Hawkes EA
    Emerging biomarkers for CD3xCD20 bispecific antibodies in lymphoma.
    Blood. 2025 Feb 12:blood.2024025772. doi: 10.1182/blood.2024025772.
    PubMed     Abstract available
    
    
    
64. CHAVEZ JC, Dickinson M, Munoz J, Ulrickson ML, et al
    Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12).
    Blood. 2025 Feb 12:blood.2024027347. doi: 10.1182/blood.2024027347.
    PubMed     Abstract available
    
    
    
65. SAMPLES L, Sadrzadeh H, Frigault MJ, Jacobson CA, et al
    Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma.
    Blood. 2025 Feb 12:blood.2024026831. doi: 10.1182/blood.2024026831.
    PubMed     Abstract available
    
    
    
66. KADY N, Abdelrahman S, Rauf AM, Burgess A, et al
    The GATA-3-dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas.
    Blood. 2025;145:597-611.
    PubMed     Abstract available
    
    
    
67. GARCIA-LACARTE M, Grijalba SC, Melchor Sanchez J, Pascual M, et al
    IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy.
    Blood. 2025 Feb 3:blood.2024025755. doi: 10.1182/blood.2024025755.
    PubMed     Abstract available
    
    
    January 2025
68. BACHY E, Linton K
    Frontline treatment of follicular lymphoma: What will it take to change current practice?
    Blood. 2025 Jan 27:blood.2024026019. doi: 10.1182/blood.2024026019.
    PubMed     Abstract available
    
    
    
69. WANG WJ, Hu Z
    CD5-positive high-grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements.
    Blood. 2025;145:455.
    PubMed    
    
    
    
70. CABALLERO GONZALEZ AC, Ujaldon-Miro C, Pujol-Fernandez P, Montserrat-Torres R, et al
    HSP-CAR30 WITH A HIGH PROPORTION OF LESS-DIFFERENTIATED T CELLS PROMOTES DURABLE RESPONSES IN REFRACTORY CD30+ LYMPHOMA.
    Blood. 2025 Jan 22:blood.2024026758. doi: 10.1182/blood.2024026758.
    PubMed     Abstract available
    
    
    
71. ZHOU T, Elenitoba-Johnson KSJ
    HLA-I aberrations in cutaneous T-cell lymphoma.
    Blood. 2025;145:252-253.
    PubMed    
    
    
    
72. YU W, Li P, Zhou L, Yang M, et al
    A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
    Blood. 2025 Jan 15:blood.2024026401. doi: 10.1182/blood.2024026401.
    PubMed     Abstract available
    
    
    
73. GOBEL C, Niccolai R, de Groot MHP, Jayachandran J, et al
    Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of Diffuse Large B-cell Lymphoma.
    Blood. 2025 Jan 10:blood.2024025500. doi: 10.1182/blood.2024025500.
    PubMed     Abstract available
    
    
    
74. BASKAR S, Peng H, Gaglione EM, Carstens EJ, et al
    Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragment covalently deposited on lymphoma cells.
    Blood. 2025 Jan 7:blood.2024024846. doi: 10.1182/blood.2024024846.
    PubMed     Abstract available
    
    
    December 2024
75. NAHARRO EF, Linden MA
    Auer rod-like inclusions in B-cell lymphoma mimicking therapy-related acute myeloid leukemia.
    Blood. 2024;144:2793.
    PubMed    
    
    
    
76. YENWONGFAI LN, Francischetti IMB
    Prominent expansion of EBV+ large B cells obscuring follicular helper T-cell lymphoma.
    Blood. 2024;144:2682.
    PubMed    
    
    
    
77. SEHN LH, Hallek M
    Introduction to a review series on high-risk aggressive lymphoma.
    Blood. 2024;144:2561-2562.
    PubMed    
    
    
    
78. DAVIES AJ
    The high-grade B-cell lymphomas: double hit and more.
    Blood. 2024;144:2583-2592.
    PubMed     Abstract available
    
    
    
79. ROSCHEWSKI M, Phelan JD, Jaffe ES
    Primary large B-cell lymphomas of immune-privileged sites.
    Blood. 2024;144:2593-2603.
    PubMed     Abstract available
    
    
    
80. DABROWSKA-IWANICKA A, Nowakowski GS
    DLBCL: who is high risk and how should treatment be optimized?
    Blood. 2024;144:2573-2582.
    PubMed     Abstract available
    
    
    
81. 
    Flavell JR, Baumforth KRN, Wood VHJ, et al. Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus-encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood. 2008;111(1):292-301.
    Blood. 2024;144:2559.
    PubMed    
    
    
    
82. LEE HJ, Ramchandren R, Friedman J, Melear JM, et al
    Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma.
    Blood. 2024 Dec 2:blood.2024024681. doi: 10.1182/blood.2024024681.
    PubMed     Abstract available
    
    
    November 2024
83. IACOBONI G, Morschhauser F
    Building the Future Management of Follicular Lymphoma with T-Cell-Redirecting Strategies.
    Blood. 2024 Nov 14:blood.2024025699. doi: 10.1182/blood.2024025699.
    PubMed     Abstract available
    
    
    
84. CHEVALIER S, Legrand C
    B-cell acute lymphoblastic leukemia with MEF2D::BCL9 rearrangement mimicking a Burkitt lymphoma.
    Blood. 2024;144:2067.
    PubMed    
    
    
    October 2024
85. IQBAL J, Inghirami G, Chan WC
    New insights into the biology of T-cell lymphomas.
    Blood. 2024;144:1873-1886.
    PubMed     Abstract available
    
    
    
86. DE LEVAL L, Gaulard P, Dogan A
    A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas.
    Blood. 2024;144:1855-1872.
    PubMed     Abstract available
    
    
    
87. MARCHI E, Craig JW, Kalac M
    Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL).
    Blood. 2024;144:1898-1909.
    PubMed     Abstract available
    
    
    
88. MOSKOWITZ AJ, Stuver RN, Horwitz SM
    Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs).
    Blood. 2024;144:1887-1897.
    PubMed     Abstract available
    
    
    
89. SEHN LH, Bartlett NL, Matasar MJ, Schuster SJ, et al
    Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after >/=2 prior therapies.
    Blood. 2024 Oct 24:blood.2024025454. doi: 10.1182/blood.2024025454.
    PubMed     Abstract available
    
    
    
90. ALDUAIJ W, Jiang A, Villa D, Collinge BJ, et al
    CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL.
    Blood. 2024 Oct 23:blood.2024025725. doi: 10.1182/blood.2024025725.
    PubMed     Abstract available
    
    
    
91. KUMAR A, Soumerai JD, Abramson JS, Barnes JA, et al
    Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation.
    Blood. 2024 Oct 22:blood.2024025563. doi: 10.1182/blood.2024025563.
    PubMed     Abstract available
    
    
    
92. HU J, Dunbar CE
    T-Cell Lymphomas in Recipients of CAR-T Cells: Assessing Risks and Causalities.
    Blood. 2024 Oct 11:blood.2024025828. doi: 10.1182/blood.2024025828.
    PubMed     Abstract available
    
    
    
93. KWANG AC, Duran GE, Fernandez-Pol S, Najidh S, et al
    Genetic alteration of class I HLA in cutaneous T-cell lymphoma.
    Blood. 2024 Oct 10:blood.2024024817. doi: 10.1182/blood.2024024817.
    PubMed     Abstract available
    
    
    
94. ALIG SK
    FISHing for clarity in double-hit lymphomas.
    Blood. 2024;144:1550-1552.
    PubMed    
    
    
    
95. 
    Friedberg JW, Bordoni R, Patel-Donnelly D, et al. Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood. 2024;143(9):786-795.
    Blood. 2024;144:1647.
    PubMed    
    
    
    
96. COLLINGE B, Ben-Neriah S, Hilton LK, Alduaij W, et al
    Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH-BCL2.
    Blood. 2024;144:1611-1616.
    PubMed     Abstract available
    
    
    
97. LAURENT C, Trisal P, Tesson B, Seth S, et al
    Follicular lymphoma comprises germinal center-like and memory-like molecular subtypes with prognostic significance.
    Blood. 2024 Oct 7:blood.2024024496. doi: 10.1182/blood.2024024496.
    PubMed     Abstract available
    
    
    
98. WALLACE DS, Loh KP, Casulo C
    How I Treat Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
    Blood. 2024 Oct 2:blood.2024024788. doi: 10.1182/blood.2024024788.
    PubMed     Abstract available
    
    
    September 2024
99. POCOCK R, Mansour MR
    T-ALL and T-LBL: a notch apart.
    Blood. 2024;144:1356-1357.
    PubMed    
    
    
    
100. TABATA R, Matsue K
     ALK-positive anaplastic large cell lymphoma, Hodgkin-like pattern with unexplained fever.
     Blood. 2024;144:1460.
     PubMed    
     
     
     
101. QUALLS DA, Armand P, Salles GA
     The current landscape of frontline large B-cell lymphoma trials.
     Blood. 2024 Sep 24:blood.2023023789. doi: 10.1182/blood.2023023789.
     PubMed     Abstract available
     
     
     
102. 
     Laurent C, Dietrich S, Tarte K. Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm. Blood. 2024;143(12):1080-1090.
     Blood. 2024;144:1349.
     PubMed    
     
     
     
103. 
     Hill LC, Rouce RH, Wu MJ, et al. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024;143(13):1231-1241.
     Blood. 2024;144:1349.
     PubMed    
     
     
     
104. ABRO B, Maurer MJ, Habermann TM, Burack R, et al
     Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO Cohort Study analysis.
     Blood. 2024 Sep 10:blood.2024025681. doi: 10.1182/blood.2024025681.
     PubMed     Abstract available
     
     
     
105. MAURER K, Grabski IN, Houot R, Gohil SH, et al
     Baseline Immune State and T-cell Clonal Kinetics are Associated with Durable Response to CAR-T Therapy in Large B-cell Lymphoma.
     Blood. 2024 Sep 6:blood.2024024381. doi: 10.1182/blood.2024024381.
     PubMed     Abstract available
     
     
     August 2024
106. ZHOU Q, Chang H
     Circulating composite B- and T-cell lymphoma.
     Blood. 2024;144:1027.
     PubMed    
     
     
     
107. WALLACE DS, Barr PM
     Ready, AIM, stop: ibrutinib plus venetoclax in MCL.
     Blood. 2024;144:800-802.
     PubMed    
     
     
     
108. BHATLA T, Hogan L MD, Teachey DT, Bautista F, et al
     Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: DELPHINUS Study.
     Blood. 2024 Aug 16:blood.2024024493. doi: 10.1182/blood.2024024493.
     PubMed     Abstract available
     
     
     
109. PABST T, Bacher U
     Boosting CAR T cells against lymphomas.
     Blood. 2024;144:689-691.
     PubMed    
     
     
     
110. CHANG CA, Emberley E, D'Souza AL, Zhao W, et al
     ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies.
     Blood. 2024;144:757-770.
     PubMed     Abstract available
     
     
     
111. WANG T, Silva O
     HHV-8+ diffuse large B-cell lymphoma with EBV coinfection occurring posttransplant.
     Blood. 2024;144:677.
     PubMed    
     
     
     
112. NIE J, Wang C, Zheng L, Liu Y, et al
     Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores antitumor efficacy in Hodgkin lymphoma.
     Blood. 2024 Aug 2:blood.2024024487. doi: 10.1182/blood.2024024487.
     PubMed     Abstract available
     
     
     
113. KUPPERS R
     MYC translocation architecture in B-NHL.
     Blood. 2024;144:469-471.
     PubMed    
     
     
     
114. ARAFAT S, Don M
     A case of Richter transformation to diffuse large B-cell lymphoma with aberrant T-cell marker expression.
     Blood. 2024;144:586.
     PubMed    
     
     
     July 2024
115. TE VRUGT M, Wessolowski JS, Randau G, Alfert A, et al
     Pediatric T-cell lymphoblastic lymphoma but not leukemia harbor TRB::NOTCH1 fusions with unfavorable outcome.
     Blood. 2024 Jul 18:blood.2024025307. doi: 10.1182/blood.2024025307.
     PubMed     Abstract available
     
     
     
116. RYAN CE, Cohen JB
     Is rituximab retro in mantle cell lymphoma?
     Blood. 2024;144:241-243.
     PubMed    
     
     
     
117. NABEEL H, Bhagat G
     Double-hit, double-expressor follicular lymphoma with plasmacytic differentiation.
     Blood. 2024;144:339.
     PubMed    
     
     
     
118. 
     Armand P, Zinzani PL, Lee HJ, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 2023;142(10):878-886.
     Blood. 2024;144:341.
     PubMed    
     
     
     
119. PICCALUGA PP
     SOX11 in EBV-negative Burkitt lymphoma.
     Blood. 2024;144:128-129.
     PubMed    
     
     
     
120. FALINI B, Lazzi S
     Mantle cell lymphoma with IRTA1+ reactive expansion of the marginal zone.
     Blood. 2024;144:237.
     PubMed    
     
     
     June 2024
121. LUCENA LAGE S, Ramaswami R, Rocco J, Rupert A, et al
     Inflammasome activation in patients with Kaposi sarcoma herpesvirus (KSHV)-associated disorders.
     Blood. 2024 Jun 28:blood.2024024144. doi: 10.1182/blood.2024024144.
     PubMed     Abstract available
     
     
     
122. BIDOT S, Feldman AL
     Herpetic lymphadenitis mimicking Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.
     Blood. 2024;143:2808.
     PubMed    
     
     
     
123. FLAIFEL A, Rocco JM
     HHV-6 lymphadenitis with DRESS syndrome: another lymphoma mimic.
     Blood. 2024;143:2671.
     PubMed    
     
     
     
124. CHRISMAN LP, Trimark PF, Pang Y, Pease DR, et al
     Updated cutaneous T-cell lymphoma TNMB staging criteria fail to identify Sezary syndrome patients with low blood burden.
     Blood. 2024 Jun 7:blood.2023023584. doi: 10.1182/blood.2023023584.
     PubMed     Abstract available
     
     
     May 2024
125. SMITH MR, Jegede O, Martin P, Till B, et al
     Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma.
     Blood. 2024 May 31:blood.2024023962. doi: 10.1182/blood.2024023962.
     PubMed     Abstract available
     
     
     
126. APAYDIN ARIKAN E, Jaffe ES
     Mantle cell lymphoma with marked plasmacytic differentiation: two contrasting faces.
     Blood. 2024;143:2337.
     PubMed    
     
     
     
127. BRINKMANN BJ, Floerchinger A, Schniederjohann C, Roider T, et al
     CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models.
     Blood. 2024 May 28:blood.2023022682. doi: 10.1182/blood.2023022682.
     PubMed     Abstract available
     
     
     
128. JAIN P, Jelloul FZ
     Biclonal mantle cell lymphoma.
     Blood. 2024;143:2217.
     PubMed    
     
     
     
129. GUPTA M, Bradley J, Massaad E, Burns E, et al
     Rapid Tumor DNA Analysis of Cerebrospinal Fluid Accelerates Treatment of Central Nervous System Lymphoma.
     Blood. 2024 May 22:blood.2024023832. doi: 10.1182/blood.2024023832.
     PubMed     Abstract available
     
     
     
130. MALINVERNI C, Bernardelli A, Glimelius I, Mirandola M, et al
     Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
     Blood. 2024 May 16:blood.2023023525. doi: 10.1182/blood.2023023525.
     PubMed     Abstract available
     
     
     
131. 
     MRD and EFS in pediatric T-lymphoblastic lymphoma.
     Blood. 2024;143:2111.
     PubMed    
     
     
     
132. 
     Silva A, Almeida ARM, Cachucho A, et al. Overexpression of wild-type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma. Blood. 2021;138(12):1040-1052.
     Blood. 2024;143:2108-2110.
     PubMed    
     
     
     
133. YUAN CT, Ma WL
     Transformed mantle cell lymphoma with additional triple-hit genotypes can be resistant to a Bruton tyrosine kinase inhibitor.
     Blood. 2024;143:2106.
     PubMed    
     
     
     
134. RIBERA JM
     MRD: also for T-lymphoblastic lymphoma.
     Blood. 2024;143:2017-2019.
     PubMed    
     
     
     
135. HILTON LK, Collinge BJ, Ben-Neriah S, Alduaij W, et al
     Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study.
     Blood. 2024 May 3:blood.2024024251. doi: 10.1182/blood.2024024251.
     PubMed     Abstract available
     
     
     
136. KIM J, Cho J, Lee MH, Yoon SE, et al
     Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis.
     Blood. 2024 May 2:blood.2023023419. doi: 10.1182/blood.2023023419.
     PubMed     Abstract available
     
     
     
137. ARORA J, Ayyappan S, Yin C, Smith BJ, et al
     T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC.
     Blood. 2024;143:1816-1824.
     PubMed     Abstract available
     
     
     April 2024
138. SARKOZY C, Callanan MB, Thieblemont C, Oberic L, et al
     Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients.
     Blood. 2024 Apr 26:blood.2024023944. doi: 10.1182/blood.2024023944.
     PubMed     Abstract available
     
     
     
139. HANDUNNETTI SM, Anderson MA, Burbury KI, Thompson PA, et al
     Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
     Blood. 2024 Apr 25:blood.2023023388. doi: 10.1182/blood.2023023388.
     PubMed     Abstract available
     
     
     
140. CROCHET G, Iacoboni G, Couturier A, Bachy E, et al
     Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.
     Blood. 2024 Apr 24:blood.2024024526. doi: 10.1182/blood.2024024526.
     PubMed     Abstract available
     
     
     
141. MAYBURY BD, James LJ BSc (Hons), Phillips N, Venkatadasari I, et al
     Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival.
     Blood. 2024 Apr 22:blood.2024024048. doi: 10.1182/blood.2024024048.
     PubMed     Abstract available
     
     
     
142. LOCKE FL, Siddiqi T, Jacobson CA, Ghobadi A, et al
     Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity.
     Blood. 2024 Apr 18:blood.2023023447. doi: 10.1182/blood.2023023447.
     PubMed     Abstract available
     
     
     
143. SUREDA-GOMEZ M, Iaccarino I, De Bolos A, Meyer MA, et al
     SOX11 expression is restricted to EBV-negative Burkitt lymphoma and associates with molecular genetic features.
     Blood. 2024 Apr 15:blood.2023023242. doi: 10.1182/blood.2023023242.
     PubMed     Abstract available
     
     
     
144. MERLIO JP
     Staphylococcus aureus and Sezary syndrome.
     Blood. 2024;143:1436-1438.
     PubMed    
     
     
     
145. WEI Q, Bueso-Ramos CE
     Thymoma with aberrant expression of CD20: a potential diagnostic pitfall of B-cell lymphoma.
     Blood. 2024;143:1551.
     PubMed    
     
     
     
146. VADIVEL CK, Willerslev-Olsen A, Namini MRJ, Zeng Z, et al
     Staphylococcus aureus induces drug resistance in cancer T cells in Sezary syndrome.
     Blood. 2024;143:1496-1512.
     PubMed     Abstract available
     
     
     
147. KROEZE E, Iaccarino I, Kleisman MM, Mondal M, et al
     Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma.
     Blood. 2024 Apr 8:blood.2024023938. doi: 10.1182/blood.2024023938.
     PubMed     Abstract available
     
     
     
148. MARCAIS A
     Targeting PD-L1 to treat ATLL?
     Blood. 2024;143:1320-1322.
     PubMed    
     
     
     
149. LOCKE FL, Oluwole OO, Kuruvilla J, Thieblemont C, et al
     Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.
     Blood. 2024 Apr 1:blood.2023021620. doi: 10.1182/blood.2023021620.
     PubMed     Abstract available
     
     
     March 2024
150. GROVER NS, Beaven AW
     T-cell lymphoma: the CAR-T revolution is coming.
     Blood. 2024;143:1201-1202.
     PubMed    
     
     
     
151. GIESSINGER J, Pullarkat ST
     An unusual presentation of lymphoplasmacytic lymphoma with isolated brachial plexus infiltration and amyloidosis.
     Blood. 2024;143:1315.
     PubMed    
     
     
     
152. 
     Zinzani PL, Thieblemont C, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142(2):141-145.
     Blood. 2024;143:1316.
     PubMed    
     
     
     
153. HILL LC, Rouce RH, Wu MJ, Wang T, et al
     Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas.
     Blood. 2024;143:1231-1241.
     PubMed     Abstract available
     
     
     
154. STEIDL C, Stevenson FK
     Introduction to a review series on the influence of the tumor microenvironment on the pathogenesis of B-cell lymphomas.
     Blood. 2024;143:1057-1058.
     PubMed    
     
     
     
155. RYAN CE, Armand P, LaCasce AS
     Frontline Treatment of Mantle Cell Lymphoma.
     Blood. 2024 Mar 18:blood.2023022352. doi: 10.1182/blood.2023022352.
     PubMed     Abstract available
     
     
     
156. GODFREY JK, Gao L, Shouse G, Song JY, et al
     Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma.
     Blood. 2024 Mar 14:blood.2024024168. doi: 10.1182/blood.2024024168.
     PubMed     Abstract available
     
     
     
157. MOLIN D
     Aging Kairos: treating older Hodgkin patients.
     Blood. 2024;143:943-945.
     PubMed    
     
     
     
158. EL HUSSEIN S
     Monomorphic epitheliotropic T-cell lymphoma with strong CD4 expression.
     Blood. 2024;143:1055.
     PubMed    
     
     
     
159. HAYASHI RJ, Hermiston ML, Wood BL, Teachey DT, et al
     MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children's Oncology Group Trial AALL1231.
     Blood. 2024 Mar 8:blood.2023021184. doi: 10.1182/blood.2023021184.
     PubMed     Abstract available
     
     
     
160. AHMED R, Feldman AL
     Occult ALK-negative anaplastic large cell lymphoma complicating chronic lymphocytic leukemia.
     Blood. 2024;143:938.
     PubMed    
     
     
     February 2024
161. SCHUSTER SJ, Huw LY, Bolen CR, Maximov V, et al
     Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
     Blood. 2024;143:822-832.
     PubMed     Abstract available
     
     
     
162. FRIEDBERG JW, Bordoni R, Patel-Donnelly D, Larson T, et al
     Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.
     Blood. 2024;143:786-795.
     PubMed     Abstract available
     
     
     
163. OLSZEWSKI AJ
     When B cells rebuff bispecifics.
     Blood. 2024;143:744-746.
     PubMed    
     
     
     
164. LYNCH RC
     Toward a cure for cHL without chemotherapy.
     Blood. 2024;143:741-742.
     PubMed    
     
     
     
165. ANG Z, Thomas-Tikhonenko A
     Lymphoma immunotherapy: the garden of forking paths.
     Blood. 2024;143:655-657.
     PubMed    
     
     
     
166. SCHOOLCRAFT DK, Karrs JX
     Flower cell morphology in high-grade B-cell lymphoma of the maxillary sinus.
     Blood. 2024;143:738.
     PubMed    
     
     
     
167. BOARDMAN AP, Palomba ML
     Does BTKi improve CAR T-cell therapy in MCL?
     Blood. 2024;143:653-655.
     PubMed    
     
     
     
168. TONINO SH, Kersten MJ
     The quest for a cure in follicular lymphoma.
     Blood. 2024;143:475-476.
     PubMed    
     
     
     
169. WINTER JN, Ferreri AJM
     Predicting outcomes in CNS lymphoma with ctDNA.
     Blood. 2024;143:478-480.
     PubMed    
     
     
     
170. HEGER JM, Mattlener J, Schneider J, Godel P, et al
     Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA.
     Blood. 2024;143:522-534.
     PubMed     Abstract available
     
     
     
171. CASULO C
     How do you define treatment success in MZL?
     Blood. 2024;143:382-383.
     PubMed    
     
     
     
172. DARNELL EP, Frigault MJ
     Two years later: CD19 CAR-T going the distance.
     Blood. 2024;143:379-380.
     PubMed    
     
     
     
173. GANDHI MK, Kelly GL
     EBNA2: a viral maestra conducting a symphony orchestra.
     Blood. 2024;143:384-385.
     PubMed    
     
     
     January 2024
174. MORSY MHA, Lilienthal I, Lord M, Merrien M, et al
     SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
     Blood. 2024 Jan 18:blood.2023022241. doi: 10.1182/blood.2023022241.
     PubMed     Abstract available
     
     
     
175. MORSY MHA, Lilienthal I, Lord M, Merrien M, et al
     SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
     Blood. 2024;143:1953-1964.
     PubMed     Abstract available
     
     
     
176. CERCHIETTI L
     Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B cell lymphoma.
     Blood. 2024 Jan 11:blood.2023021002. doi: 10.1182/blood.2023021002.
     PubMed     Abstract available
     
     
     
177. COPPO P, Ricard L
     Plasmablastic lymphoma: better refine prognosis.
     Blood. 2024;143:101-102.
     PubMed    
     
     
     
178. DREYLING M, Fowler NH, Dickinson M, Martinez-Lopez J, et al
     Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update.
     Blood. 2024 Jan 9:blood.2023021567. doi: 10.1182/blood.2023021567.
     PubMed     Abstract available
     
     
     
179. RADTKE A, Roschewski M
     The follicular lymphoma tumor microenvironment at single cell and spatial resolution.
     Blood. 2024 Jan 9:blood.2023020999. doi: 10.1182/blood.2023020999.
     PubMed     Abstract available
     
     
     December 2023
180. BARRACLOUGH A, Hawkes EA
     Tribulations of trials in aggressive lymphoma.
     Blood. 2023;142:2232-2234.
     PubMed    
     
     
     
181. VEELKEN H
     Energy overpowers sweet tooth in FL.
     Blood. 2023;142:2226-2229.
     PubMed    
     
     
     
182. CHIBA M, Shimono J, Suto K, Ishio T, et al
     Whole genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in Adult T-cell leukemia/lymphoma.
     Blood. 2023 Dec 24:blood.2023021423. doi: 10.1182/blood.2023021423.
     PubMed     Abstract available
     
     
     
183. SHEA L, Mehta-Shah N
     Peripheral T-cell lymphoma: Are all patients high-risk?
     Blood. 2023 Dec 24:blood.2023020912. doi: 10.1182/blood.2023020912.
     PubMed     Abstract available
     
     
     
184. FU L, Gong S
     KMT2A-rearranged B-lymphoblastic leukemia/lymphoma with surface light chain restriction and lacking immature markers.
     Blood. 2023;142:2220.
     PubMed    
     
     
     
185. LAURENT C, Dietrich S, Tarte K
     Cell crosstalk within lymphoma tumor microenvironment: follicular lymphoma as a paradigm.
     Blood. 2023 Dec 14:blood.2023021000. doi: 10.1182/blood.2023021000.
     PubMed     Abstract available
     
     
     
186. SPAARGAREN M
     What's brewing for MALT1 in lymphoma?
     Blood. 2023;142:1939-1941.
     PubMed    
     
     
     
187. LUU BE, Xu SA
     A peculiar case of cyclin D1-positive lymphoplasmacytic lymphoma.
     Blood. 2023;142:2034.
     PubMed    
     
     
     
188. WIMBERGER N, Ober F, Avar G, Grau M, et al
     Oncogene-induced MALT1 protease activity drives posttranscriptional gene expression in malignant lymphomas.
     Blood. 2023;142:1985-2001.
     PubMed     Abstract available
     
     
     November 2023
189. RAUERT-WUNDERLICH H
     EGR1 changes course in B-cell lymphoma.
     Blood. 2023;142:1850-1851.
     PubMed    
     
     
     
190. CAI J, Lee J
     Cold agglutinin syndrome with unexpected bone marrow CD5+ diffuse large B-cell lymphoma.
     Blood. 2023;142:1935.
     PubMed    
     
     
     
191. ALDERUCCIO JP, Nayak L, Cwynarski K
     How I treat secondary CNS involvement by aggressive lymphomas.
     Blood. 2023;142:1771-1783.
     PubMed     Abstract available
     
     
     
192. STEVENSON FK PROFESSOR, Forconi F
     The essential microenvironmental role of oligomannoses inserted into the antigen-binding sites of lymphoma cells.
     Blood. 2023 Nov 22:blood.2023022703. doi: 10.1182/blood.2023022703.
     PubMed     Abstract available
     
     
     
193. GHESQUIERES H, Krzisch D, Nicolas Virelizier E, Kanoun S, et al
     Phase 2 LYSA study of prednisone, vinblastine, doxorubicin, bendamustine for untreated older Hodgkin lymphoma patients.
     Blood. 2023 Nov 18:blood.2023021564. doi: 10.1182/blood.2023021564.
     PubMed     Abstract available
     
     
     
194. DUELL J, Leipold AM, Appenzeller S, Fuhr V, et al
     Sequential Antigen-loss and Branching Evolution in Lymphoma after CD19- and CD20-Targeted T-cell Redirecting Therapy.
     Blood. 2023 Nov 17:blood.2023021672. doi: 10.1182/blood.2023021672.
     PubMed     Abstract available
     
     
     
195. MURAKAMI MA
     Toward rational therapy for mantle cell lymphoma.
     Blood. 2023;142:1504-1506.
     PubMed    
     
     
     
196. ETANCELIN P, Boussaid I
     Two sides of the same coin: transdifferentiation from Burkitt lymphoma to histiocytic sarcoma.
     Blood. 2023;142:1576.
     PubMed    
     
     
     October 2023
197. ABRAMSON JS, Palomba ML, Gordon LI, Lunning MA, et al
     Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
     Blood. 2023 Oct 27:blood.2023020854. doi: 10.1182/blood.2023020854.
     PubMed     Abstract available
     
     
     
198. MINSON AG, Hamad N, Cheah CY, Tam CS, et al
     CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study.
     Blood. 2023 Oct 26:blood.2023021306. doi: 10.1182/blood.2023021306.
     PubMed     Abstract available
     
     
     
199. BROCKELMANN PJ
     AXL-erating mantle cell lymphoma treatment.
     Blood. 2023;142:1411-1412.
     PubMed    
     
     
     
200. GINI G, Tani M, Tucci A, Marcheselli L, et al
     Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study.
     Blood. 2023;142:1438-1447.
     PubMed     Abstract available
     
     
     
201. NEELAPU SS, Chavez JC, Sehgal A, Epperla N, et al
     Three-Year Follow-Up Analysis of Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5).
     Blood. 2023 Oct 25:blood.2023021243. doi: 10.1182/blood.2023021243.
     PubMed     Abstract available
     
     
     
202. COLLINS GP
     Tackling PD1i resistance in Hodgkin lymphoma.
     Blood. 2023;142:1333-1334.
     PubMed    
     
     
     
203. BELADA D, Kopeckova K, Bergua Burgues JM, Stevens D, et al
     Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
     Blood. 2023;142:1348-1358.
     PubMed     Abstract available
     
     
     
204. LEOPIZZI M, Mundo L, Messina E, Campolo F, et al
     Epstein-Barr virus encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma.
     Blood. 2023 Oct 17:blood.2023021346. doi: 10.1182/blood.2023021346.
     PubMed     Abstract available
     
     
     
205. DI CIACCIO PR, Polizzotto MN, Cwynarski K, Gerrie AS, et al
     The Influence of Immunodeficiency, Disease Features and Patient Characteristics on Survival in Plasmablastic Lymphoma.
     Blood. 2023 Oct 13:blood.2023021348. doi: 10.1182/blood.2023021348.
     PubMed     Abstract available
     
     
     
206. BOMMIER C, Zucca E, Chevret S, Conconi A, et al
     Early Complete Response as Validated Surrogate Marker in Extranodal Marginal Zone Lymphoma Systemic Therapy.
     Blood. 2023 Oct 6:blood.2023020984. doi: 10.1182/blood.2023020984.
     PubMed     Abstract available
     
     
     
207. RUSSLER-GERMAIN DA, Cliff ERS, Bartlett NL
     Cell-of-Origin Effect of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma: No Ordinary Subgroup Analysis.
     Blood. 2023 Oct 5:blood.2023022048. doi: 10.1182/blood.2023022048.
     PubMed     Abstract available
     
     
     
208. 
     Jain MD, Ziccheddu B, Coughlin CA, et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 2022;140(5):491-503.
     Blood. 2023;142:1255.
     PubMed    
     
     
     
209. MANDATO E, Yan Q, Ouyang J, Paczkowska J, et al
     MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8.
     Blood. 2023;142:1219-1232.
     PubMed     Abstract available
     
     
     September 2023
210. 
     Balsas P, Veloza L, Clot G, et al. SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma. Blood. 2021;138(22):2202-2215.
     Blood. 2023;142:1173-1176.
     PubMed    
     
     
     
211. NARITA K, Takeuchi K
     FISH for EBV genome in a patient with diffuse large B-cell lymphoma harboring t(14;18)(q32;q21).
     Blood. 2023;142:1172.
     PubMed    
     
     
     
212. ZHOU N, Busino L
     Targeting epigenetics and ferroptosis in DLBCL.
     Blood. 2023;142:1108-1109.
     PubMed    
     
     
     
213. DIEPSTRA A, Nolte IM, van den Berg A, Magpantay LI, et al
     Elevated serum TARC levels precede classic Hodgkin lymphoma diagnosis by several years.
     Blood. 2023 Sep 25:blood.2023020959. doi: 10.1182/blood.2023020959.
     PubMed     Abstract available
     
     
     
214. LIU Y, Kimpara S, Hoang NM, Daenthanasanmak A, et al
     EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B cell lymphoma.
     Blood. 2023 Sep 22:blood.2023020142. doi: 10.1182/blood.2023020142.
     PubMed     Abstract available
     
     
     
215. QUALLS DA, Lambert N, Caimi PF, Merrill MH, et al
     Tafasitamab and lenalidomide in large B cell lymphoma: real-world outcomes in a multicenter retrospective study.
     Blood. 2023 Sep 22:blood.2023021274. doi: 10.1182/blood.2023021274.
     PubMed     Abstract available
     
     
     
216. FREEMAN CL, Locke FL
     CARs put age in the rearview mirror.
     Blood. 2023;142:1029-1031.
     PubMed    
     
     
     
217. 
     Williams AM, Salehabadi SM, Xing M, et al. Modifiable risk factors for neurocognitive and psychosocial problems after Hodgkin lymphoma. Blood. 2022;139(20):3073-3086.
     Blood. 2023;142:1028.
     PubMed    
     
     
     
218. ZHOU N, Choi J, Grothusen G, Kim BJ, et al
     DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance.
     Blood. 2023;142:973-988.
     PubMed     Abstract available
     
     
     
219. HAEBE SE, Day G, Czerwinski DK, Sathe A, et al
     Follicular lymphoma evolves with a surmountable dependency on acquired glycosylation motifs in the B cell receptor.
     Blood. 2023 Sep 8:blood.2023020360. doi: 10.1182/blood.2023020360.
     PubMed     Abstract available
     
     
     
220. CHEAH CY
     Pembrolizumab: a key for some, but not all, HL.
     Blood. 2023;142:861-862.
     PubMed    
     
     
     
221. 
     Panea RI, Love CL, Shingleton JR, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019;134(19):1598-1607.
     Blood. 2023;142:940.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.